The federal Food and Drug Administration October 3 approved a new daily PrEP pill that could offer a safer option for some individuals at risk for HIV, but the indication does not cover everyone who ...

A new HIV prevention option works well for gay and bisexual men and transgender women and should be approved by the Food and Drug Administration for these populations, according to an expert advisory ...

Because Truvada and Descovy already exist as effective PrEP options, it was considered unethical to include a placebo group. Zero cases of HIV infection were reported among women in the lenacapavir ...

The U.S. Food and Drug Administration approved the second drug to help prevent HIV infections on Thursday. Descovy is a PrEP or pre-exposure prophylaxis drug, which means the drug is taken daily to ...

In June, Gilead Sciences announced impressive early results from its PURPOSE 1 trial, which showed 100 percent efficacy of lenacapavir in preventing new HIV infections among cisgender women in ...

(Reuters) - An FDA advisory panel on Wednesday voted in favour of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex ...

Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy ...

Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human Services Department is evaluating plans to slash the federal government funding ...